

Project ECHO for Interstitial Lung Disease

Wednesday, May 3, 2023, 7am-8am

| | |
|------------------------|--|
| Medical Director | Robert Hallowell, MD |
| Principal Investigator | Aliaa Barakat, PhD |
| Didactic Speaker | Barry Shea, MD |
| Session Facilitator | Peter LaCamera, MD |
| Target Audience | The series is designed for pulmonologists and radiologists, and for other health providers who care for people with ILD. |

In accordance with HIPAA: All patient information will be de-identified during session.

| Time | Didactic Presentation / Case Discussion | Presenter / Facilitator |
|---------------|--|--|
| 7:00am-7:05am | Announcements and Introductions | Aliaa Barakat, PhD Robert Hallowell, MD |
| 7:05am-7:25am | Didactic: More Than Meds — Nonpharmacologic Treatments for ILD | Barry Shea, MD |
| 7:25am-8:00am | Case Presentation and Discussion | Peter LaCamera, MD |
| 8am | Closing Remarks | Arthur Dea, CCRP |



In support of improving patient care, this activity has been planned and implemented by the Pulmonary Care and Research Collaborative, Ltd. and Project ECHO®. Project ECHO® is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.



JOINTLY ACCREDITED PROVIDER™
INTERPROFESSIONAL CONTINUING EDUCATION

AMA Designation Statement

Project ECHO® designates this live activity for a maximum of 1.0 *AMA PRA Category 1 Credit™*. Physicians should claim only credit commensurate with the extent of their participation in the activity.

ECHO Activity ID: RSS330

This session will be audio and video recorded.
Your participation confirms your consent to this recording.

Disclosure Statement

Project ECHO®, in compliance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, requires that anyone who is in a position to control the content of an educational activity disclose all relevant financial relationships they have had within the last 24 months with an ineligible company.

None of the following planners / presenters for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Arthur Dea, BA, CCRP; Fiona Gibbons, MD.

The following planners / presenters listed below have disclosed that they have a relevant financial relationship with an ineligible company.

| Name | Nature of Relationship | Name of Ineligible Company |
|----------------------|---|--|
| Aliaa Barakat, PhD | Principal Investigator of investigator-initiated research | Genentech, Inc. |
| Katharine Black, MD | Basic Science Researcher | Celgene/Bristol Myers Squibb, Bayer AG |
| Leo Ginns, MD | Site Principal Investigator for multicenter clinical trial | Nitto Denko |
| Robert Hallowell, MD | Site Principal Investigator or Co-Investigator for multicenter clinical trial | Galapagos NV, Hoffmann-La Roche, Nitto Denko |
| | Former Medical Advisory Board Member | Boehringer Ingelheim |
| | Editor and/or Content Contributor | Dynamed, UpToDate |
| Peter LaCamera, MD | Principal Investigator of investigator-initiated research | Boehringer Ingelheim |
| | Site Principal Investigator for multicenter clinical trial | Galapagos NV, Boehringer Ingelheim, Theravance Biopharma, Bristol Myers Squibb |
| Barry Shea, MD | Site Principal Investigator for multicenter clinical trial | Galapagos NV, FibroGen |

All of the relevant financial relationships listed for these individuals have been mitigated.

ECHO Activity ID: RSS330

This session will be audio and video recorded.
Your participation confirms your consent to this recording.